PCVX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

PCVX ▲ +8.24% at T+20d

NEUTRAL call ✓ call won +8.24% · α vs SPY +0.82% · entry $55.94 → $60.55

Next anchor: T+60d in 7d

Last close $46.33 (close Jun 8) · -17.18% from $55.94 entry

Entry anchored
Mar 23, 08:15 AM ET
via Databento tick

T+1d

-2.27%

call -2.27% · α -1.91%

$54.67

settled 3mo ago

T+5d

-1.75%

call -1.75% · α +1.81%

$54.96

settled 2mo ago

T+20d

+8.24%

call +8.24% · α +0.82%

$60.55

settled 7w ago

T+60d

—

call — · α —

—

in 7d

Price Chart

Loading chart...

Executive Summary

Vaxcyte announced completion of enrollment in the OPUS-1 and OPUS-2 Phase 3 trials for its investigational 31-valent pneumococcal vaccine VAX-31. Topline data from OPUS-1 is expected in Q4 2026, with OPUS-2 and OPUS-3 results anticipated in H1 2027. The trials are designed to support a future Biologics License Application (BLA) submission to the FDA, building on prior Breakthrough Therapy designation for VAX-31 in preventing invasive pneumococcal disease and pneumonia.

Actionable Insight

Monitor for topline data from OPUS-1 in Q4 2026, which could be a major catalyst. Until then, no new efficacy or safety data to assess; current market cap reflects future potential, not near-term fundamentals.

Key Facts

Enrollment completed in OPUS-1 (n≈4,000) and OPUS-2 (n≈1,300) Phase 3 trials for VAX-31.
Topline data from OPUS-1 expected in Q4 2026; OPUS-2 and OPUS-3 results expected in H1 2027.
OPUS-1 is a pivotal noninferiority trial comparing VAX-31 to Capvaxive® (PCV21) and Prevnar 20® (PCV20) in adults ≥50 years.
VAX-31 has FDA Breakthrough Therapy Designation for prevention of both IPD and pneumococcal pneumonia in adults.
No clinical results or financial figures reported — this is a program update on trial enrollment.

Financial Impact

No immediate financial impact; potential long-term value if VAX-31 demonstrates superiority and gains approval.

revenuevaluationR&D spend

Risk Factors

Clinical trial results may not meet endpoints despite favorable Phase 1/2 data.
Regulatory delays or failure to obtain BLA approval even with positive data.
High market expectations already priced in given $7.9B market cap despite being pre-revenue.

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3260381

7 reports for PCVX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for PCVX — sortable, filterable
	Type				Now
Jun 2, 2026 7d ago	Press Release NEUTRAL ★ 4/10	$46.93 $48.76	▲ +3.90%	▲ +3.49%	$46.33 (−1.28%)
May 6, 2026 4w ago	8-K BEARISH ★ 7/10	$51.48 $53.01	▼ −2.97%	▼ −2.14%	$46.33 (+10.00%)
Apr 23, 2026 6w ago	DEFA14A NEUTRAL ★ 3/10	$59.49 $59.72	▲ +0.39%	▲ +0.22%	$46.33 (−22.12%)
Apr 1, 2026 10w ago	Insider Cluster NEUTRAL ★ 3/10	$58.50 $58.38	▼ −0.21%	▼ −0.28%	$46.33 (−20.80%)
Mar 23, 2026 11w ago	Press Release NEUTRAL ★ 4/10	$55.94 $54.67	▼ −2.27%	▼ −1.91%	$46.33 (−17.18%)
Feb 24, 2026 15w ago	8-K NEUTRAL ★ 4/10	$63.04 $60.00	▼ −4.82%	▼ −4.28%	$46.33 (−26.51%)
Feb 24, 2026 15w ago	8-K NEUTRAL ★ 5/10	$63.04 $60.00	▼ −4.82%	▼ −4.28%	$46.33 (−26.51%)

US Market Status

Market Closed — Opens in 6h 39m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access